• News
  • SAN DIEGO
  • BioTech

Auspex to test Huntington's drug

La Jolla’s Auspex Pharmaceuticals (Nasdaq: ASPX) has signed up the planned 90 patients for its Phase 3 clinical trial of SD-809, a potential treatment of chorea associated with Huntington's disease.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments
Subscribe Today!